Purpose We previously observed that American ginseng berry and ginsenoside Re attenuated cisplatininduced emesis in a rat model, suggesting that the herb may have a value in treating chemotherapy-induced nausea/vomiting. However, it is not clear whether consuming ginseng concurrently with chemotherapy aVects the eYcacy of chemotherapeutic agents. In this study, we explored if the ginseng extract and its constituents, ginsenosides Rb 1 , Rb 3 , and Re, alter tumoricidal activity of cisplatin in human cancer cells. Methods Tumoricidal eVects of cisplatin, and/or American ginseng berry extract (AGBE) and ginsenosides Rb 1 , Rb 3 , and Re, on human breast carcinoma MCF-7 cells were measured as cell proliferation in vitro. Cell counts were performed in MCF-7 cells pretreated with test agents for 72 h. Results Cisplatin decreased MCF-7 cell proliferation signiWcantly in a concentration-dependent manner. Compared to control group, cisplatin reduced the cell proliferations to 56.5 §3.3% at 1 g/ml, to 36.6 §2.4% at 5 g/ml, and to 26.9 §2.4% at 15 g/ml (P<0.01). AGBE also inhibited the cell proliferation signiWcantly, although in a less extended manner. When the berry extract at 0.5 mg/ml was used with cisplatin at 1 g/ml, a signiWcant enhancement of cisplatin's activity was observed (35.8 §2.5%; P<0.05). We also observed that Rb 1 did not change cisplatin's activity; Rb 3 , at a higher concentration, increased cisplatin's anti-proliferation activity (48.0 §1.2%; P<0.05); Re increased cisplatin's activity (Re 0.1 mg/ml, 48.0 §2.8%; Re 0.3 mg/ml, 31.9 §2.2%, P<0.01). Conclusion Our data suggest that AGBE and the tested ginsenosides do not attenuate cisplatin's tumoricidal activity in MCF-7 cells, but in fact may actually enhance it. Additionally, the ginseng extract and ginsenoside Re by themselves exerted antiproliferative activity against MCF-7 cells. The herb might potentially serve a complementary role with the chemotherapeutic agents in treating cancer, in addition to decreasing chemotherapy-induced nausea/ vomiting.
Introduction
Treatment of cancer with chemotherapeutic agents such as cisplatin is associated with severe adverse eVects. The drug-related adverse events not only worsen patients' quality of life but can also lead to their refusal to continue the potentially curative chemotherapy [20, 27] . Nausea/vomiting is one of the most signiWcant adverse eVects of chemotherapy [27] . It is vital to adequately control this drug-induced symptom and the anticipatory emesis of subsequent chemotherapy cycles [27] . The currently available anti-emetic drugs can relieve the symptoms especially when used in combinations, but lead to the possibility of additional adverse events and potential drug-drug interactions causing a reduction in the eYcacy of chemotherapeutic agents [12, 32, 33] . Recently, we reported that the berry extract of American ginseng (Panax quinquefolius L.) and its major constituent, ginsenoside Re, attenuated cisplatin-induced emesis in a rat model, and demonstrated the potential value of the herb in treating chemotherapy-induced nausea/vomiting [21] . Patients with cancer often resort to complementary and alternative medical means to treat the side eVects of chemotherapy [24] . It therefore appears that American ginseng berry extract (AGBE) may have a clinical utility in this setting.
As an anti-oxidant herb, ginseng's eVect on cisplatininduced adverse eVects could be linked to its anti-oxidant activity [13, 21, 30] . However, to date, it is not clear if consuming anti-oxidants concurrently with chemotherapy hampers or helps the tumoricidal activity of chemotherapeutic agents [14] . In this study, we evaluated whether American ginseng extract and its active constituents, ginsenosides Rb 1 , Rb 3 , and Re, alter tumoricidal activity of cisplatin in human breast carcinoma MCF-7 cells [25] , which are sensitive to cisplatin.
Materials and methods

Preparation and analysis of AGBE
American ginseng berry (Wisconsin Ginseng Board, Wausau, WI, USA) was cultivated under standard conditions. The dried berry, obtained from a single batch, was ground into Wne powder, dispersed in 75% ethanol, sonicated and reXuxed for 1 h at 50°C [28] . The extraction procedure was repeated three times. The cooled mixture was Wltered through Whatman No. 1 paper (Maidstone, England) and the Wltrate was collected. The Wnal residue was washed with ethanol and the solution was combined with the extract. The ethanol extract was dried under vacuum with rotary evaporator R-205 (Buchi Labortechnik AG, Flawil, Schweiz), dissolved in water, and extracted with watersaturated butanol (three times). The butanol layers were combined, washed with water, evaporated under vacuum, and freeze-dried.
High-performance liquid chromatography (HPLC) was conducted to conWrm the ginsenoside proWle of the AGBE using a Liquid Chromatography System of Waters model 2960 (Milford, MA, USA), with a quaternary pump, automatic injector, a 996 photodiode array detector, and Waters Millennium 32 software for peak identiWcation and integration. Ginsenosides were separated on a Phenomenex Prodigy ODS (2), 5 m, 150£3.2 mm analytical column (Phenomenex, Torrance, CA, USA) [34, 35] . The separation of ginsenosides was obtained at room temperature by gradient elution using acetonitrile (A) and water (B) as eluents. Gradient elution started with 20% solvent A and 80% solvent B, changed to 20.3% A for 25 min, then changed to 26.8% A for 3 min and held for 26 min; changed to 35.6% A for 20 min; changed to 50% A for 11 min; changed to 68% A for 10 min; changed to 95% A for 1 min and held for 3 min; changed to 20% A for 3 min and held for 8 min. The absorbance was measured at 202 nm using the photodiode array detector. Figure 1 shows a chromatogram of AGBE assayed by HPLC, and three selected ginsenosides in AGBE.
Ginsenosides Rb 1 and Re, with purity of >98%, were obtained from IndoWne Chemical Company (Somerville, NJ, USA). Ginsenoside Rb3, with purity of >95%, was obtained from Delta Information Center for Natural Organic Compounds (Xuancheng, China).
Cell and culture conditions
The human breast carcinoma MCF-7 cells (ATCC, Manassas, VA, USA) were routinely grown in Dulbecco's modiWcation of Eagle's minimal essential medium (DMEM), supplemented with 10% fetal bovine serum and penicillin-streptomycin (50 unit/ml; Invitrogen, Carlsbad, CA, USA). Cells were maintained in a tissue culture dish (100 mm in diameter) and kept in a humidiWed incubator (5% CO 2 in air at 37°C). Medium was changed every 2-3 days. When the cells reached 80-90% conXuence, they were trypsinized, harvested, and seeded into a new tissue culture dish [6, 15, 19] .
Cell proliferation assay
To examine the anti-proliferative eVect of the test agents, MCF-7 cells were seeded in a 24-well plate at approximately 10,000 cells/well with regular DMEM medium and allowed to adhere for 24 h. After adhesion of MCF-7 cells, the culture medium was changed prior to the addition of drugs. The MCF-7 cells were incubated with testing material at various concentrations for 72 h. Control cultures were incubated in medium alone. At the end of treatments, MCF-7 cells were detached using trypsin and counted using a Coulter Counter (Coulter Electronics, Hialeah, FL, USA) [5, 7] . On selected days after the removal of the incubation medium, the cell monolayer was washed twice with phosphate buVered saline. All assays were performed at least three times. The percentage of MCF-7 carcinoma cell proliferation was calculated as follows: cell proliferation (%) = 100 £ (cell number in experimental well/cell number in the control well).
Statistical analysis
Data are expressed as mean § standard error. Statistical analysis was performed using analysis of variance followed by a post hoc test for comparison of means. DiVerences were considered signiWcant if P<0.05.
Results
Tumoricidal eVect of cisplatin on MCF-7 carcinoma cells
The tumoricidal activity of cisplatin on MCF-7 carcinoma cells is shown in Fig. 2 . Cisplatin decreased MCF-7 carcinoma cell proliferation signiWcantly in a concentration-dependent manner. Compared to control group (100%), cisplatin reduced the cell proliferations to 56.5 §3.3% at 1 g/ml, to 36.6 §2.4% at 5 g/ml, and to 26.9 §2.4% at 15 g/ml (P<0.01). Cisplatin at a dose of 1 g/ml was selected for studying the interaction between cisplatin and ginseng. Figure 2 also shows the eVects of AGBE on MCF-7 cells. AGBE inhibited the cell proliferation signiWcantly as well, although in a less extended manner. Compared to control group, AGBE reduced the cell proliferations to 90.4 §3.6% at 0.1 mg/ml, and to 66.7 §3.0% at 0.5 mg/ml (P<0.01).
EVect of AGBE on cisplatin's tumoricidal activity As shown in Fig. 3 , compared to cisplatin alone at 1 g/ ml (56.5 §3.3%), cisplatin at 1 g/ml plus AGBE at Control is normalized to 100%. **, P<0.01, compared to control. Cisp cisplatin, AGBE American ginseng berry extract 0.1 mg/ml elicited an increasing trend in anti-proliferation activity (49.1 §3.2%). When AGBE at 0.5 mg/ml was used with the same concentration of cisplatin, a signiWcant change was observed (35.8 §2.5%; P<0.05 compared to cisplatin alone). These data suggest that AGBE does not attenuate cisplatin's tumoricidal activity. Rather, at a concentration of 0.5 mg/ml, AGBE enhanced the tumoricidal activity of cisplatin on MCF-7 cells.
Interaction between cisplatin and ginsenosides on MCF-7 carcinoma cells
To explore which ginsenosides in AGBE play a major role in the additive eVects of cisplatin's tumoricidal activity, three ginsenosides were tested (Fig. 4) . While, ginsenoside Rb 1 did not change cisplatin's activity signiWcantly, ginsenoside Rb 3 , at a higher concentration, increased cisplatin's activity (48.0 §1.2; P<0.05). We also observed that ginsenoside Re increased cisplatin's activity in a concentration-related manner (Re 0.1 mg/ ml, 48.0 §2.8; Re 0.3 mg/ml, 31.9 §2.2, P<0.01).
Discussion
Ginseng has been used for centuries in Oriental countries as a panacea that promotes longevity [2, 11, 17] , and is considered reasonably safe [8] . There are mainly two diVerent kinds of ginseng based on their geographical location of cultivation, i.e., Asian ginseng and American ginseng. Both of them show comparable properties of restoring and enhancing normal wellbeing and are thereby collectively known as adaptogens [2, 11, 17] . In this study, we used American ginseng, one of the most commonly consumed herbs in the United States [3] . The berry of ginseng, which was reported in our previous investigation as reducing chemotherapy-induced nausea/vomiting [21] , was used in this study. We have also previously demonstrated that the berry has a signiWcantly higher content of total ginsenosides than the root of ginseng [35] .
In our previous study, an anti-emetic eVect of AGBE was observed using a cisplatin-induced rat model, and our data suggest that this eVect was mediated through the extract's anti-oxidant activity [21] . Clinically, speciWc beneWcial eVects such as anti-ischemic, anti-hypertensive and immune modulating eVects have been attributed to the use of ginseng [16, 30] . These pharmacological eVects are, to a signiWcant extent, also considered to be due to the anti-oxidant properties of the herb [22] . Kitts et al. reported that American ginseng exhibited eVective anti-oxidant activity in both lipid-soluble and water-soluble medium by chelating metal ions and through the direct scavenging of DPPH and hydroxyl radicals in an in vitro study [13] . In addition to anti-oxidant properties, American ginseng also stimulates NO (nitric oxide) release, which could modulate the anti-oxidant activity [11] . The mechanism of tumoricidal action of cisplatin is similar to that of the alkylating group of drugs and is achieved through DNA cross-linking [37] . Thus, the chemotherapeutic activity of cisplatin is not mainly mediated through oxygen radical generation. However, oxygen radical production is a signiWcant adverse event that occurs with cisplatin treatment and results in tissue injury [26, 29, 36] . Administering anti-oxidants could treat the oxidant-mediated side eVects but might have possible interactions with the tumoricidal actions of cisplatin [14] . Interactions of cisplatin with the antioxidant, N-acetyl cysteine, demonstrated an inhibition of anti-tumor activity [14] . On the contrary, other antioxidants, such as quercetin and glutathione, showed a trend towards greater tumor response or anti-tumor activity [1, 14] . Other investigators have shown that anti-oxidant treatment could help to prevent gastrointestinal toxicity, nephrotoxicity, and ototoxicity, without aVecting the anti-cancer activity [4, 36] . L-Carnitine prevented cisplatin-induced oxidant injury of the kidneys and intestines while preserving cisplatin's tumoricidal activity in a rat model [4] . It thus appears that the outcomes of interaction between cisplatin and anti-oxidants depend on the speciWc anti-oxidants. Since the anti-proliferative activity of ginseng in MCF-7 cells appears to be mediated by arresting cell cycle, it should not interfere with cisplatin's anti-tumor activity [23] . In the present study, we observed that the interaction between ginseng and cisplatin is complementary.
Ginsenosides are active constituents in ginseng [2] , and some ginsenosides have individually exhibited anti-oxidant properties [10, 18] . Ginseng root has a relatively high content of Rb 1 compared to that of ginseng berry, while the berry has signiWcantly higher contents of Rb 3 and Re [31] . Corbit et al. recently observed an anti-proliferative eVect of American ginseng root on MCF-7 cells [9] . In this study, the eVects of AGBE and selected ginsenosides on cisplatin's tumoricidal activity were individually tested in the MCF-7 cell line. Our data showed that Re has a signiWcant additive eVect on cisplatin's activity, and that Re could be responsible for the ginseng berry's positive interaction with cisplatin.
Cisplatin is used extensively as an eVective chemotherapeutic agent in treating a variety of cancers. Our data demonstrated that the ginseng berry extract and Re possess tumoricidal activity and contribute an additive eVect to cisplatin's activity. The anti-cancer eVect of ginseng increases the likelihood that the anti-oxidant herb might serve a complementary role with the chemotherapeutic agents in treating cancer, in addition to potentially decreasing chemotherapy-induced nausea/vomiting. Cancer patients are known to use herbal products more often than the general populace [24] , and thus, well-investigated herbal therapies can oVer patients with a practical alternative.
